Novozymes A/S (OTCMKTS:NVZMY) Short Interest Down 60.1% in May

Novozymes A/S (OTCMKTS:NVZMY) was the recipient of a significant decrease in short interest in the month of May. As of May 29th, there was short interest totaling 12,291 shares, a decrease of 60.1% from the May 14th total of 30,830 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average trading volume of 83,894 shares, the days-to-cover ratio is presently 0.1 days.

Analyst Upgrades and Downgrades

NVZMY has been the topic of several research analyst reports. Rothschild & Co Redburn upgraded shares of Novozymes A/S to a “strong-buy” rating in a research report on Friday, March 27th. Kepler Capital Markets raised shares of Novozymes A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 13th. Finally, Zacks Research raised shares of Novozymes A/S from a “strong sell” rating to a “hold” rating in a research note on Monday. Two equities research analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy”.

Novozymes A/S Trading Down 0.5%

Shares of Novozymes A/S stock traded down $0.31 during mid-day trading on Friday, hitting $59.68. The stock had a trading volume of 5,719 shares, compared to its average volume of 85,924. Novozymes A/S has a 12-month low of $49.90 and a 12-month high of $75.99. The firm has a market cap of $24.74 billion, a P/E ratio of 40.32, a price-to-earnings-growth ratio of 1.13 and a beta of 0.95. The firm has a 50-day moving average of $59.39 and a two-hundred day moving average of $60.41. The company has a quick ratio of 1.03, a current ratio of 1.67 and a debt-to-equity ratio of 0.27.

Novozymes A/S (OTCMKTS:NVZMY) last released its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.51 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.31). The company had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $1.32 billion. Novozymes A/S had a net margin of 14.22% and a return on equity of 6.52%. Sell-side analysts forecast that Novozymes A/S will post 2.43 earnings per share for the current year.

About Novozymes A/S

Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.

The company’s product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).